Where is Alnylam located in the US?
Alnylam Pharmaceuticals maintains a highly centralized and concentrated operational footprint within the United States, with the vast majority of its core activities—including research, development, and corporate management—situated in Cambridge, Massachusetts. The company’s primary U.S. presence is centered in the Kendall Square area of Cambridge, which is internationally recognized for its density of biotech firms and proximity to elite scientific research institutions. While the company maintains a national sales and medical affairs field force to reach physicians and patients across the country, its physical infrastructure is intentionally clustered in the Cambridge biotech corridor. This location allows the company to integrate its clinical research, regulatory operations, and commercial strategy within a singular high-tech industrial ecosystem, ensuring seamless cooperation among its scientists and strategic leaders.
Related FAQs
ALS Limited (operating globally as ALS Global) employs approximately 18,000 to 19,000 people across its extensive testing, inspection, and certification operations.
The global biopharmaceutical and innovative medicine landscape is anchored by massive research-driven enterprises that generate tens of billions in annual revenue through advanced drug development.
Pfizer’s legendary cholesterol-lowering medication Lipitor (atorvastatin) holds the historical crown as the most lucrative pharmaceutical product ever commercialized, generating tens of billions of dollars in cumulative global revenue throughout its ...
Dallas Cowboys owner and prominent wildcatter Jerry Jones has invested more than 1.1 billion US dollars into Comstock Resources, a major natural gas producer operating heavily across North America.
Alnylam Pharmaceuticals has faced intense biopharmaceutical industry debates and intellectual property patent disputes regarding its pioneering RNA interference therapeutic technologies.
Alnylam Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States. Situated in one of the world's premier clusters for biotechnology and life sciences research, the company's corporate campus is located in Kendall Square.
Novo Nordisk, a major Danish multinational pharmaceutical enterprise headquartered in Bagsværd, Denmark, is the creator and manufacturer of Ozempic (semaglutide).
Evaluating the stock volatility and market risk profile of Ambarella, Inc.—a fabless semiconductor company specializing in low-power video compression and computer vision processors—reveals an exceptionally high-beta, volatile profile.
Determining whether Alnylam Pharmaceuticals represents a buy or sell recommendation involves reviewing consensus equity research ratings from biotechnology and healthcare analysts.
Bill Clinton did not pay off the total U.S. national debt. However, his administration is noted for being the only one between 1970 and 2018 to pay down the debt held by the public.
Alnylam Pharmaceuticals, Inc. (traded on the NASDAQ under the ticker ALNY) trades at a live market price of approximately $216.07 per share.
Assessing Alnylam Pharmaceuticals as an equity investment reveals a cutting-edge biotechnology pioneer specializing in RNA interference therapies designed to treat rare and prevalent genetic diseases.
AltaGas Ltd. is performing exceptionally well, underpinned by robust operational results across its utility and midstream infrastructure segments.
Determining whether Albemarle warrants a strong buy recommendation depends on shifting consensus ratings from chemical and mining equity analysts tracking commodity cycles.